ArticleFrontiers in medicine2026
Successful live birth in a woman with partial 17α-hydroxylase/17,20 lyase deficiency: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: 17a-hydroxylase/17,20-lyase deficiency (17-OHD) is a rare form of congenital adrenal hyperplasia caused by mutations in the CYP17A1 gene, resulting in impaired activity of the corresponding enzymes. Its typical manifestations include hypertension, hypokalemia, and disorders of sexual development. Cases presenting with atypical clinical manifestations are exceedingly rare and affected individuals are susceptible to being overlooked or misdiagnosed. Additionally, successful pregnancies in such cases have rarely been reported. Case presentation: We described a 28-year-old Chinese female diagnosed with partial 17-OHD, which was confirmed by genetic testing, and achieved a successful pregnancy through assisted reproductive technology. The onset was highly insidious, where she presented with infertility as the initial symptom, and an abnormally high level of progesterone and recurrent ovarian cysts were noted, without typical symptoms of 17-OHD. Further blood test demonstrated the low levels of testosterone, dehydroepiandrosterone, and androstenedione, and increased levels of 17-hydroxyprogesterone, follicle-stimulating hormone, luteinizing hormone, and adrenocorticotropic hormone. Genetic testing revealed that the patient harbored a rare compound heterozygous mutation in the CYP17A1 gene: c.1169C>G (p. Thr390Arg) and c.1073G>A (p. Arg358Gln). Following glucocorticoids standardization therapy, successful conception was achieved via Conclusion: 17-OHD with atypical manifestations is extremely rare and highly prone to misdiagnosis. For women with infertility accompanied by abnormal progesterone and 17-hydroxyprogesterone levels, the possibility of 17-OHD should be ruled out. Standardized treatment with glucocorticoids and assisted reproductive technology could be considered when needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.